In a Phase 1 clinical study, researchers led by EPFL and their partners report that a new liver- and gut-targeted oral drug can safely lower triglycerides and other blood lipids. When we eat, our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results